News & Events
CyBorD-Dara Study
CyBorD-Dara Study
18 patients with newly diagnosed multiple myeloma were treated on the BCNI CyBorD-DARA study with a combination of the anti-CD38 monoclonal antibody Daratumumab, the proteosome inhibitor bortezomib, cyclophosphamide and dexamethasone. Treatment was consolidation by an autologous stem cell transplant and 2 further cycles of CyBorD-DARA, followed by 12 months of maintenance Daratumumab. The treatment was safe and effective, with a progression free survival of 81% after maintenance and a 2-year overall survival of 89%. 78% of patients achieved a complete response and 38% had undetectable disease (meaning <1 cancer cell in 100,000 cells tested, called minimal residual disease) after transplant, which was sustained until the end of treatment. The full study results were published in Clinical Lymphoma, Myeloma and Leukaemia Journal in 2022.
